CARMA FUND
CARMA FUND I is an early-stage investment fund for advancing Life Science and Healthcare technologies. The fund started off with a First Closing in June 2022 and has €56M under management. It is based in Munich and Frankfurt am Main. Starting to develop new products and services for the patients’ well-being and medical advancements comes with its unique challenges and opportunities. Biotech/healthcare is a specialist business and as such innovators have often struggled to rope in reliant streams of outside capital necessary for quick and effi cient development towards a market entry. The Fund was initiated by the two technology transfer companies Innovectis (Frankfurt) and Ascenion (Munich).
Ansprechpartner
Dr. Martin Raditsch
General Partner
Capital under management
CARMA has €56M under management.
Investment requirements and financing offer
CARMA FUND I is uniquely suited for young Eurpean companies and projects from the Life Science and medical space due to an extra-long term, flexible investment modes and its relationships with leading technology transfer offi ces and industry partners.
CARMA invests in pre-seed, seed, and series A.
Industry focus
CARMA FUND is investing in opportunities from the European Life Science and Healthcare sector.
THERAPEUTICS
MEDTECH
DIAGNOSTICS
DIGITAL HEALTH
Portfolio and exits
Acorai, Aignostics, Allogenetics, Akribion, Ceregate, Dimericon Therapeutics, Epignostix, Genome Biologics, Incontalert, Kupando, O11 Medical, Salvina, Symphera, Tecregen, Thryve, Elkedonia
Memberships in networks/associations
ASTP: This association is Europe’s association of knowledge transfer professionals with two decades of experience in educating, connecting and advocating for the profession.
bioRN, the science and industry innovation cluster in the Rhine-Neckar region around Heidelberg
Date of foundation/ Number of employees
June 2022/4
Kontaktdaten
Address: Herzogstrasse 64, München 80803
Telephone: +49 15153946465
E-Mail: martin.raditsch@carma-fund.com
Social Media: www.linkedin.com/in/martin-raditsch
Web Address: www.carma-fund.com
- Part III: The Best Asset Doesn’t Have a Passport
- Part II: The Best Asset Doesn’t Have a Passport
- GCC-/MENA-Märkte für Europas Life Sciences
- Part I: The Best Asset Doesn't Have a Passport
- EU Inc.: An der Schwelle zur Börsennotierung
- BayOConnect: Why don't we try to be the best?
- European Life Sciences Coalition: Europas Investoren richten den Blick nach Brüssel
- Epitome Therapeutics: 4 Mio. EUR für Feinsteuerung der Genaktivität
- Case Study: OptoGenTech – Hören mit Licht
- IQM Quantum Computers
- Case Study: BIONCaRT – Stammzellen für die Regeneration geschädigter Gelenke
- Bayerns Biotech: Viel Geld, wenig Gewissheit
- Der deutsche Biotech-Teufelskreis
- Kicker, Kick-Off, Kapital
- Ach, ach Amerika: Anpassung statt Abkehr
- Veraxa: BiTAC, Börsengang, Bewährungsprobe
- Biotech 2025: Resilient an der Oberfläche, fragil im Fundament
- Der Biotech IP Flip: Skalieren statt Verkaufen
- Partnerschaften als Motor für Transformation und Wachstum
- Darwin AG zieht Jahresprognose zurück

